Stocks and Investing
Stocks and Investing
Wed, July 8, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Downgraded (VRTX) to Hold and Increased Target to $300 on, Jul 8th, 2020
Matthew Harrison of Morgan Stanley, Downgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Hold and Increased Target from $277 to $300 on, Jul 8th, 2020.
Matthew has made no other calls on VRTX in the last 4 months.
There are 14 other peers that have a rating on VRTX. Out of the 14 peers that are also analyzing VRTX, 2 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $264 on, Monday, July 6th, 2020
- Geoffrey Porges of "SVB Leerink" Maintained at Hold with Increased Target to $263 on, Thursday, April 30th, 2020
These are the ratings of the 12 analyists that currently disagree with Matthew
- Salveen Richter of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $330 on, Thursday, July 2nd, 2020
- Robyn Karnauskas of "Citigroup" Maintained at Strong Buy with Increased Target to $325 on, Friday, June 12th, 2020
- Jasper Hellweg of "Argus Research" Maintained at Strong Buy with Increased Target to $320 on, Friday, May 15th, 2020
- Kevin Huang of "CFRA" Maintained at Strong Buy with Increased Target to $297 on, Thursday, April 30th, 2020
- Liisa Bayko of "JMP Securities" Maintained at Buy with Increased Target to $285 on, Thursday, April 30th, 2020
- Paul Matteis of "Stifel" Maintained at Strong Buy with Increased Target to $285 on, Thursday, April 30th, 2020
- Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $283 on, Thursday, April 30th, 2020
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $295 on, Thursday, April 30th, 2020
- Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $305 on, Thursday, April 30th, 2020
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Increased Target to $298 on, Tuesday, April 21st, 2020
- Gena Wang of "Barclays" Initiated at Buy on, Friday, March 20th, 2020
- Alethia Young of "Cantor Fitzgerald" Reiterated at Buy with Increased Target to $275 on, Wednesday, March 11th, 2020
Contributing Sources